Peter Heydemann to Muscular Dystrophy, Duchenne
This is a "connection" page, showing publications Peter Heydemann has written about Muscular Dystrophy, Duchenne.
Connection Strength
0.468
-
A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. J Neuromuscul Dis. 2022; 9(1):39-52.
Score: 0.198
-
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 09 23; 390(10101):1489-1498.
Score: 0.145
-
Under-recognition of Low Blood Pressure Readings in Patients with Duchenne Muscular Dystrophy. Pediatr Cardiol. 2015 Oct; 36(7):1489-94.
Score: 0.125